Brought to you by 
Sandoz to commercialize Pear's reSET digital therapeutics to combat substance abuse; Pear later regains rights
24 Jun 2021
Executive Summary
Sandoz International GMBH will lead the commercialization of Pear Therapeutics Inc.'s reSET for substance use disorder (SUD) and reSET-O for opioid use disorder (OUD).
Deal Industry
- Digital Health
- Medical Devices
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sandoz to commercialize Pear's reSET digital therapeutics to combat substance abuse; Pear later regains rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice